Cargando…

Correction to: Durvalumab: A Review in Extensive-Stage SCLC

Detalles Bibliográficos
Autor principal:	Al-Salama, Zaina T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783897/ https://www.ncbi.nlm.nih.gov/pubmed/34870785 http://dx.doi.org/10.1007/s11523-021-00863-w

Ejemplares similares

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
por: Chen, Yuanbin, et al.
Publicado: (2022)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC
por: Tapan, Umit, et al.
Publicado: (2020)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2023)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma
por: Shionoya, Yosuke, et al.
Publicado: (2021)

Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
por: Machiyama, Hirotomo, et al.
Publicado: (2023)

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
por: Asao, Tetsuhiko, et al.
Publicado: (2022)

Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2023)

SCLC extensive disease – treatment guidance by extent or/and biology of response?
por: Eckert, Franziska, et al.
Publicado: (2008)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Zhang, Cuifen, et al.
Publicado: (2023)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
por: Sathiyapalan, Arani, et al.
Publicado: (2022)

Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stage SCLC: A Case Report
por: Wu, Shuang, et al.
Publicado: (2022)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
por: Song, Peng-Fei, et al.
Publicado: (2020)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
por: Wang, Yang, et al.
Publicado: (2023)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
por: Hanna, Catherine R., et al.
Publicado: (2021)

Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Liu, Wenhui, et al.
Publicado: (2022)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
por: Melillo, Giovanni, et al.
Publicado: (2021)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Correction: Extensive eczema herpeticum in a previously well child
por: Almoalem, Manal, et al.
Publicado: (2022)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): a population based outcome study
por: Soon, Yu Yang, et al.
Publicado: (2018)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Correction to: Extension osteotomy of the metacarpal I and ligamentoplasty of the trapeziometacarpal joint for the treatment of early‑stage osteoarthritis and instability of the trapeziometacarpal joint
por: Honigmann, Philipp, et al.
Publicado: (2023)

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
por: Arriola, Edurne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_me69adu2b3mh3g2p1s0i9p50v9